{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Bright Minds Biosciences Inc."},"Symbol":{"label":"Symbol","value":"DRUG"},"Address":{"label":"Address","value":"19 VESTRY STREET, NEW YORK, New York, 10013, United States"},"Phone":{"label":"Phone","value":"+1 647 865-8622"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin."},"CompanyUrl":{"label":"Company Url","value":"https://www.brightmindsbio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Ian B. McDonald","title":"President, Chief Executive Officer & Director"},{"name":"Jan Torleif Pedersen","title":"Director & Chief Scientific Officer"},{"name":"Mark A. Smith","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}